Sophie McGrath is a partner in the London office of Brown Rudnick and advises on a wide range of corporate matters, including private and public financings, mergers and acquisitions, public offerings, restructurings and general corporate advice.

A strong focus of her practice is in the venture capital and private equity sector, acting for companies at all stages of development, as well as investors and management teams. Sophie's practice covers a range of industries, although she has particular experience in the life sciences, technology and impact investment sectors.  Sophie is also a member of the Global Brands Group.

Sophie also has a keen interest in the Social Enterprise sector and has authored a Guide with Thomson Reuters on the corporate forms available in England and Wales for Social Enterprises. She acts for many Social Enterprises on a pro bono basis, giving them advice on their establishment and ongoing corporate governance.

Sophie is a member of the British Venture Capital Association’s’ Impact Investment advisory group, which has a mandate to promote the development of the impact investment sector in the UK.

Sophie is a recommended lawyer for Venture Capital and M&A in the Legal 500 UK and was nominated for the "Corporate - Rising Star" Award at the 2013 Euromoney Women in Business Law Awards.



Advising N+1 Singer as nominated adviser and broker to Verona Pharma plc, a listed drug development company, in relation to its £44.7 million UK and US placing.

Advising a listed life sciences company in relation to its acquisition of a medical devices business based in the United States.

Advising Cruncher Technologies Limited, a company using artificial intelligence to solve big data issues for the financial markets, on various financing rounds and its commercialisation into the US.

Advising Neuroprotexeon Limited, a late clinical-stage pharmaceutical and medical device company, on its initial spinout from Imperial College London, subsequent rounds of private financing and issues relating to the cross border nature of its operations.

Advised Gilde Healthcare Partners B.V. as lead investor on multiple financing rounds into Qinec Limited, a digital healthcare company.

Advised Mustard Seed, an impact investment fund on multiple investments including:

  • Skin Healthcare, a skin analytics app and device designed to help identify early signs of skin cancer
  • Beulah, a luxury goods company providing employment opportunities to victims of human trafficking
  • Switchee, a company seeking to significantly reduce energy use and spending

Advised Novo A/S, Lundbeckfond A/S and Gilde Heathcare Partners B.V. on multiple financing rounds into Acacia Pharma Limited, a specialty pharmaceutical company focused on the development and commercialisation of new treatments for the conditions arising as a consequence of surgery, cancer or cancer treatment.

Advised Arc Medical Limited, a UK medical devices company, on a partial exit by certain shareholders to Norgine Ventures, along with a strategic investment and working capital facility from Norgine.

Advised EQ Investors, a B Corporation certified wealth manager (B Corporations are for-profit companies certified as meeting rigorous standards of social and environmental performance, accountability, and transparency), in relation to the acquisition of Truestone Wealth Management, a financial planning firm with £500 million of client assets under management.

Advised a European consortium of healthcare investors including Wellington Partners, Seroba Kernel, NBGI Ventures and B2V in relation to a £27 million Series B financing round into Quanta Fluid Solutions, a medical device company focused on haemodialysis systems for use in the clinic and home.

Advised Novo A/S on a €100 million investment in Symphogen A/S, a Danish biotech company that specialises in the development of recombinant antibody therapies for the treatment and prevention of disease.

Bar Admissions

England & Wales
New South Wales, Australia
Quoted in “Brexit shatters hopes for patents watchdog in London”, The Sunday Times¸ 21 August 2016
"Brexit – Life Sciences Update”, Brown Rudnick Alert, 16 August 2016
Quoted in “Biotech start-ups look to crowd funding”, Financial Times, 16 February 2016
"Going Public", European Biopharmaceutical Review, April 2014
"The Rise and Rise of Social Enterprise", Real Business, 28 September 2012
"European VC Grinds to a Halt", Financial News, 10 July 2012
"Industry Tackles Pipeline Issues with Revised R&D", Financial News, 30 April 2012
"Mid Market to Drive Tech M&A", Financial News, 16 January 2012
Professional Affiliations
British Venture Capital Association
Biotech Industry Association
One Nucleus, European Life Sciences Association
Anglo-Australasian Lawyers Society
Awards and Honors
Sophie has extensive experience in private investment work, acting for companies at all stages of development, as well as investors and management teams. Sophie is a recommended lawyer in Legal 500 2017 in the fields of M&A: Smaller Deals, up to £50m who describe her as "very easy to work with""sensible and pragmatic".
Sophie is recommended in the Legal 500 2017 for Venture Capital and is described as "very resourceful and knowledgeable".
Sophie was recommended in the Legal 500 2016 for Venture Capital and is described as providing 'an excellent all-round service' to clients active in the life sciences, technology and cleantech sectors.
Recommended as a leading lawyer for Venture Capital, and Pharmaceuticals and Biotechnology in the Legal 500 UK 2015.
Nominated for the "Corporate - Rising Star" Award at the 2013 Euromoney Women in Business Law Awards.